PTLF
Based in Los Angeles, California, Petlife Pharmaceuticals, Inc. is dedicated to the discovery, formulation, commercialization, and ongoing support of both medicinal drugs and nutritional supplements for pets. Their primary focus is on addressing canine and feline cancer and various autoimmune conditions, such as arthritis, within the United States market. The company's leading product is Vitalzul, which functions by obstructing the formation of new blood vessels crucial for the growth of solid tumors. Petlife is also progressing the development of Vitalzul into a potent, prescription-only oral medication, as well as a highly concentrated version for direct intravenous or injectable application to tumors. Additionally, their offerings extend to developing palatable treats suitable for dogs and cats.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2018 Q2 | -0.01 | $0 | -$162,454 |
| 2017 Q1 | -0.01 | $0 | -$119,942 |
| 2017 Q4 | 0.00 | $0 | $114,280 |
| 2017 Q3 | -0.01 | $0 | -$93,789 |
| 2017 Q2 | -0.03 | $0 | -$156,881 |
| 2016 Q1 | -0.88 | $0 | -$182,528 |
| 2016 Q4 | 0.00 | $0 | -$151,839 |
| 2016 Q3 | -0.02 | $0 | $0 |